| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Cereblon
The primary molecular target of Pomalidomide-amino-PEG4-NH2 hydrochloride is cereblon (CRBN), an E3 ubiquitin ligase substrate receptor. As a ligand for the E3 ubiquitin ligase complex, this compound binds to CRBN and recruits the ubiquitin-proteasome system. In the context of PROTAC technology, the pomalidomide moiety serves as the E3 ligase recognition element, while the PEG4-NH2 linker provides a handle for conjugation to a target protein ligand. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[2].
In vitro studies demonstrate that Pomalidomide-amino-PEG4-NH2 hydrochloride functions as a key component in PROTAC molecules. The compound contains a pomalidomide-based cereblon ligand that binds to the E3 ubiquitin ligase and a PEG4-NH2 linker that can be conjugated to a target protein ligand. The PEG4 spacer provides appropriate length and flexibility for the formation of the ternary complex between the target protein, PROTAC, and E3 ligase. This compound is designed to facilitate targeted protein degradation in cellular systems through the ubiquitin-proteasome pathway. |
| ln Vivo |
In vivo activity data for Pomalidomide-amino-PEG4-NH2 hydrochloride as a standalone compound are not reported, as it is utilized as a synthetic intermediate or linker component in PROTAC design rather than as a therapeutic agent itself. The in vivo efficacy of PROTAC molecules incorporating this pomalidomide-based ligand and PEG4 linker would depend on the specific target protein ligand and the overall pharmacokinetic properties of the complete PROTAC construct.
|
| Enzyme Assay |
In vitro assays for evaluating Pomalidomide-amino-PEG4-NH2 hydrochloride typically involve binding studies to assess its interaction with cereblon (CRBN), the E3 ubiquitin ligase substrate receptor. Surface plasmon resonance (SPR) or fluorescence polarization techniques can be used to measure the binding affinity (Kd) between the pomalidomide-based ligand and CRBN. Competition binding assays using fluorescently labeled probes are also commonly used to determine the inhibitory concentration (IC50) of the ligand for CRBN binding.
|
| Cell Assay |
In vitro cell-based assays for Pomalidomide-amino-PEG4-NH2 hydrochloride typically involve its incorporation into PROTAC molecules followed by evaluation of target protein degradation in cultured cells. Cells are treated with PROTACs containing this pomalidomide-based ligand and PEG4 linker, and the levels of the target protein are measured by Western blotting or immunofluorescence to assess degradation efficiency. Dose-response experiments are performed to determine the DC50 (half-maximal degradation concentration) of the PROTAC construct.
|
| Animal Protocol |
In vivo animal studies using Pomalidomide-amino-PEG4-NH2 hydrochloride are conducted as part of the evaluation of complete PROTAC molecules that incorporate this pomalidomide-based ligand and PEG4 linker. Typical protocols involve administering PROTAC constructs to mouse xenograft models or disease-relevant animal models, followed by assessment of target protein degradation in harvested tissues via Western blot or immunohistochemistry. Pharmacodynamic endpoints include measurement of target protein levels and tumor growth inhibition.
|
| ADME/Pharmacokinetics |
As a linker conjugate rather than a therapeutic drug, comprehensive pharmacokinetic data for Pomalidomide-amino-PEG4-NH2 hydrochloride alone are limited. The compound has a molecular formula of C23H31ClN4O9 and a molecular weight of 542.96. It has a purity of ≥97%. The chemical name is 14-amino-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide hydrochloride.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Pomalidomide-amino-PEG4-NH2 hydrochloride as an individual compound is not extensively characterized, as it is primarily used as a research reagent and synthetic intermediate for PROTAC development. The compound is intended for research use only and is not approved for therapeutic use in humans. Pomalidomide is known to have immunomodulatory effects and teratogenic potential, and appropriate safety precautions should be taken.
|
| References | |
| Additional Infomation |
Pomalidomide-amino-PEG4-NH2 hydrochloride (CAS 2331259-45-9) has a molecular formula of C23H31ClN4O9 and a molecular weight of 542.96. It is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology. The compound has a purity of 99.27%. It is part of the E3 ligase ligand-linker conjugate category.
|
| Molecular Formula |
C23H31CLN4O9
|
|---|---|
| Molecular Weight |
542.97
|
| Exact Mass |
542.177
|
| CAS # |
2331259-45-9
|
| Related CAS # |
Pomalidomide-amino-PEG4-NH2;2331259-44-8
|
| PubChem CID |
139035831
|
| Appearance |
White to yellow solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
37
|
| Complexity |
809
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)COCCOCCOCCOCCN.Cl
|
| InChi Key |
HFCHLXYVKQEGTC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H30N4O9.ClH/c24-6-7-33-8-9-34-10-11-35-12-13-36-14-19(29)25-16-3-1-2-15-20(16)23(32)27(22(15)31)17-4-5-18(28)26-21(17)30;/h1-3,17H,4-14,24H2,(H,25,29)(H,26,28,30);1H
|
| Chemical Name |
2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]acetamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~250 mg/mL (~460.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (11.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 6.25 mg/mL (11.51 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8417 mL | 9.2086 mL | 18.4172 mL | |
| 5 mM | 0.3683 mL | 1.8417 mL | 3.6834 mL | |
| 10 mM | 0.1842 mL | 0.9209 mL | 1.8417 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
